MedTrace Logo

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-04-14

No results posted yet for this study

Summary

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SNV1521

SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

DRUG

DB-1310

DB-1310 is given as an infusion. Dose and frequency are dependent upon treatment arm.

DRUG

Abiraterone

Abiraterone is taken orally. Dose and frequency are per approved prescribing instructions.

DRUG

Darolutamide

Darolutamide is taken orally. Dose and frequency are per approved prescribing instructions.

Sponsors & Collaborators

  • Synnovation Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-23
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • France
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06220864 on ClinicalTrials.gov